Cytosurge Elects Biotech Veteran Luba Greenwood to Board as It Builds Causal Data Foundation for AI Drug Discovery
核心洞察
Cytosurge (搜索) has elected veteran biotech executive and investor Luba Greenwood, J.D., to its Board of Directors, effective July 9, 2026, to support commercial growth and US expansion.
Greenwood, currently CEO of Mwyngil Therapeutics (搜索) and former executive at Verily (搜索), Roche, and Dana-Farber's venture fund, brings decades of leadership across biotech, pharma, and AI.
Cytosurge (搜索)'s patented FluidFM® OMNIUM platform enables Same-Cell Biology by biopsying living cells without killing them, generating causal rather than correlational data for AI-driven drug discovery.
Cytosurge (搜索), the Zurich-based pioneer of Same-Cell Biology, announced on July 20, 2026, the election of Luba Greenwood, J.D., to its Board of Directors, effective July 9, 2026. Greenwood, a distinguished veteran biotech executive, investor, and company builder, joins the board as the company scales its proprietary technology platform and commercial reach while expanding its generation of causal biological data to fuel next-generation AI-driven drug discovery.
Greenwood brings decades of leadership experience spanning biotechnology, pharmaceuticals, deep technology, life sciences, and artificial intelligence. She currently serves as CEO of Mwyngil Therapeutics (搜索) and holds prominent board seats including MassBio. Her extensive background in venture capital, including founding and running Dana-Farber's venture fund, is expected to be instrumental as Cytosurge (搜索) expands its US footprint and engages strategic investors.
Closing the Causal Gap in AI Drug Discovery
Cytosurge (搜索) aims to solve what it describes as a critical bottleneck in AI drug discovery: the reliance on endpoint data that captures correlation rather than causation. Through its patented FluidFM® technology powering the FluidFM® OMNIUM platform, the company safely biopsies a living cell without killing it to generate same-cell data, providing a true before-and-after readout of the exact same living cell following a perturbation.
"Every AI lab racing to simulate biology is about to hit the same wall: their models train on endpoint data that captures correlation, not causation, a major reason why most drug candidates still fail in the clinic," said Greenwood. "No amount of scale or computing fixes that. Cytosurge (搜索), with its proprietary technology and forward-looking team, is positioned to generate the missing ingredient: true causal data. Whoever accumulates it first owns the layer beneath all of digital biology."
Greenwood further emphasized the significance of the approach: "This approach measures a living cell before and after intervention, turning cellular uncertainty into causal evidence. Behind it is a team of engineers, biologists, and data scientists united by one conviction: that understanding how individual cells respond to intervention is the foundation better medicines depend on."
Leadership Perspective and Commercial Momentum
"We are thrilled to welcome Luba at such a pivotal moment," said Simon Egli, CEO of Cytosurge (搜索). "As AI drug discovery matures, the industry is realizing that computing power alone can't close the causal gap. Luba's expertise makes her the ideal partner as we grow our platform and expand our footprint, particularly in the US market."
Cytosurge (搜索) is already monetizing its data layer through active Live-seq as a Service offerings and pharma engagements spanning oncology biomarker discovery and target validation. The FluidFM® technology is currently present in more than 140 research labs across leading universities, life science institutes, and pharmaceutical companies worldwide, supported by over 130 peer-reviewed publications and a Nature-validated methodology that has earned deep scientific trust.
Platform Capabilities and Service Offerings
The FluidFM® OMNIUM platform supports applications including live-cell sequencing, longitudinal molecular analysis, and single-cell manipulation. Cytosurge (搜索) provides two distinct service offerings: CellEDIT, a vector-free CRISPR service using direct nuclear injection to safely engineer challenging cell types while preserving cell viability and relevant biological characteristics; and Live-seq as a Service, which reveals the true causal drivers of drug response, resistance, and target validation.
As its installed base and publication record continue to compound, the company is building the counterfactual models that pharmaceutical partners need to identify the right targets and doses, positioning itself at the intersection of single-cell biology and artificial intelligence-driven therapeutic development.